Cancer Profiling Market Anticipated To Witness Robust Growth, Surpassing $23.08 Billion By 2029

The Cancer Profiling Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Cancer Profiling Market Size and Its Estimated Growth Rate?
In recent years, there has been a rapid expansion in the cancer profiling market size. The market, which stood at $13.48 billion in 2024, is predicted to surge to $15.05 billion by 2025, registering a compound annual growth rate (CAGR) of 11.6%. This growth during the historical spell can be attributed to the surge in cancer cases, increased utilization of precision medicine techniques, the clinical acceptance of biomarkers, the advancement and targeting of drug therapies, heightened awareness, and patient advocacy.

The size of the cancer profiling market is set to significantly expand in the coming years, reaching $23.08 billion in 2029 with a compound annual growth rate (CAGR) of 11.3%. This forecasted growth is due to the use of artificial intelligence in the field, worldwide research collaborations, the development of liquid biopsy applications, supportive regulatory bodies for precision medicine, and intensified focus on earlier detection. The forecast period is also expecting to see trends such as the prevalence of liquid biopsy, comprehensive genomic profiling, the emergence of immunoprofiling, collaborative networks for data sharing, and single-cell sequencing.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9912

How Are Emerging Segments Shaping the Cancer Profiling Market Landscape?
The cancer profiling market covered in this report is segmented -

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization
2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers
3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers
4) By Application: Research Applications, Clinical Applications, Screening, Diagnostics, Prognostics, Other Applications

Subsegments:
1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology, Radioimmunoassays
2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)
3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)
4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays
5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

Which Growth Factors Are Influencing Cancer Profiling Market Expansion?
The growth of the cancer profiling market is being driven by the increasing prevalence of cancer. The prevalence of cancer is defined as the total number of new cancer diagnoses in a certain population over a certain time period. Urbanization, aging populations, changes in lifestyle, and environmental and genetic factors all contribute to the rise in cancer incidence. Cancer profiling is useful in identifying specific genetic or molecular changes in a tumor, like gene mutations or other alterations in tumor DNA, which are beneficial in treating cancer. For example, in 2022, the American Cancer Society, a US-based volunteer organization, predicted that there would be 1.9 million new diagnoses of cancer and 609,360 cancer-related deaths in the United States. Hence, the growth of the cancer profiling market is being fueled by this uptick in the incidence of cancer.

Who Are the Dominant Players Across Different Cancer Profiling Market Segments?
Major companies operating in the cancer profiling market include Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., Oncomine Dx Target Test, OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

What Are the Latest Developing Trends in the Cancer Profiling Market?
Key players in the cancer profiling market are emphasizing on innovative developments such as broad coverage. This kind of test investigates 517 cancer-associated genes in nearly 30 types of solid tumors. Broad coverage implies a thorough examination of various genetic alterations, biomarkers, or molecular targets. For example, Illumina, Inc., a biotech firm based in the US, launched the TruSight Oncology Comprehensive (TSO) test in March 2022, signaling a major progress in cancer diagnostics. This new in vitro diagnostic test used in Europe profiles cancer mutations to help steer patients towards specific therapies. It involves the analysis of both DNA and RNA across 517 genes in almost 30 solid tumor types. With a turnaround of four to five days, the test provides quicker results and is CE-marked for European quality standards, thereby reducing the need for several gene assays on various tissue samples.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Which Geographic Regions Are Expected to Dominate the Cancer Profiling Market in the Coming Years?
North America was the largest region in the cancer profiling market in 2024. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Cancer Profiling Market?
2. What is the CAGR expected in the Cancer Profiling Market?
3. What Are the Key Innovations Transforming the Cancer Profiling Industry?
4. Which Region Is Leading the Cancer Profiling Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.